Side by side
ARA-290 vs KPV
Both are discussed for healing & recovery. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| ARA-290 | KPV | |
|---|---|---|
| What it is | An eleven-amino-acid fragment of erythropoietin that keeps the tissue-repair signalling and drops the blood-thickening. Studied properly in nerve damage, with a published randomised trial. | A three-amino-acid fragment of alpha-MSH studied for anti-inflammatory effects, largely in animal models of gut inflammation. |
| EvidenceHow much human evidence exists, not how well it works. | Clinical trials | Preclinical |
| Regulatory statusReviewed 2026-08-16 | Not approved for any indication. Has completed randomised phase 2 trials in neuropathy and holds orphan drug designation for sarcoidosis in both the United States and the European Union. Material sold as a research chemical is not the clinical product. | Not approved for human use in the United States. Sold only as a research chemical. |
| Routes | Subcutaneous | Subcutaneous, Oral, Topical |
| Half-life | 0.1 hours | 1 hours |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $2.25/mg | $1.40/mg |
| Median per mg | $5.15/mg | $4.50/mg |
| Vendors with a price | 26 | 52 |
| Storage once mixed | Refrigerated at 2–8 °C. Do not freeze once mixed. | Refrigerated at 2–8 °C. Do not freeze once mixed. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.